Heparanase in inflammation and inflammation‐associated cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Recent years have seen a growing body of evidence that enzymatic remodeling of heparan sulfate proteoglycans profoundly affects a variety of physiological and pathological processes, including inflammation, neovascularization, and tumor development. Heparanase is the sole mammalian endoglycosidase that cleaves heparan sulfate. Extensively studied in cancer progression and aggressiveness, heparanase was recently implicated in several inflammatory disorders as well. Although the precise mode of heparanase action in inflammatory reactions is still not completely understood, the fact that heparanase activity is mechanistically important both in malignancy and in inflammation argues that this enzyme is a candidate molecule linking inflammation and tumorigenesis in inflammation‐associated cancers. Elucidation of the specific effects of heparanase in cancer development, particularly when inflammation is a causal factor, will accelerate the development of novel therapeutic/chemopreventive interventions and help to better define target patient populations in which heparanase‐targeting therapies could be particularly beneficial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
Heparan sulphate proteoglycans fine-tune mammalian physiology
Bishop, J. R., Schuksz, M., & Esko, J. D. (2007) · Nature · doi:10.1038/nature05817 · Cited by 1,631
Joyce, J. A., Freeman, C., Meyer-Morse, N., Parish, C. R., & Hanahan, D. (2005) · Oncogene · doi:10.1038/sj.onc.1208602 · Cited by 163
A Synthetic Heparanase Inhibitor Reduces Proteinuria in Passive Heymann Nephritis
Levidiotis, V., Freeman, C., Punler, M., Martinello, P., Creese, B., Ferro, V., van der Vlag, J., Berden, J. H. M., Parish, C. R., & Power, D. A. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000142426.55612.6d · Cited by 59
Cited by
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
“Phosphomanno-pentose sulfate (PI-88) is a drug that went through clinical trials and targets inflammatory cells (also endothelial cells) [102].”
BackgroundAnders, H.-J., & Schaefer, L. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010117 · Cited by 330
Snow, A. D., Cummings, J. A., & Lake, T. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.710683 · Cited by 84
Jendresen, C., Digre, A., Cui, H., Zhang, X., Vlodavsky, I., Li, J.-P., & Nilsson, L. N. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-40999-4 · Cited by 19
Metadata
- Authors
- Meirovitz, A., Goldberg, R., Binder, A., Rubinstein, A. M., Hermano, E., & Elkin, M.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2013-03-04
- Volume
- 280
- Issue
- 10
- Pages
- 2307-2319
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W1968152808
- Cited by
- 82
- References
- 4
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.